How the fast-food industry is responding in the booming era of GLP-1s

With the use of GLP-1 medications skyrocketing in the United States, you’d be forgiven for thinking the new weight loss era could sound a death knell for America’s fast food industry.

Instead, chains are adapting to cater to those who have helped grow GLP-1s into a multi-billion-dollar industry. Novo Nordisk – the company behind Ozempic, Wegovy and Rybelsus – reported $31.1 billion in revenue from the medications in 2024, up from $11.9 billion in 2022.